|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dikomey E, Brammer I, Johansen J, Bentzen
SM and Overgaard J: Relationship between DNA double-strand breaks,
cell killing, and fibrosis studied in confluent skin fibroblasts
derived from breast cancer patients. Int J Radiat Oncol Biol Phys.
46:481–490. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeggo PA and Löbrich M: Contribution of
DNA repair and cell cycle checkpoint arrest to the maintenance of
genomic stability. DNA Repair (Amst). 5:1192–1198. 2006. View Article : Google Scholar
|
|
4
|
Cann KL and Hicks GG: Regulation of the
cellular DNA double-strand break response. Biochem Cell Biol.
85:663–674. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Endicott JA and Noble ME: Structural
characterization of the cyclin-dependent protein kinase family.
Biochem Soc Trans. 41:1008–1016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Canavese M, Santo L and Raje N: Cyclin
dependent kinases in cancer: Potential for therapeutic
intervention. Cancer Biol Ther. 13:451–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diaz-Padilla I, Siu LL and Duran I:
Cyclin-dependent kinase inhibitors as potential targeted anticancer
agents. Invest New Drugs. 27:586–594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M, Pevarello P, Barbacid M and
Bischoff JR: CDK inhibitors in cancer therapy: What is next? Trends
Pharmacol Sci. 29:16–21. 2008. View Article : Google Scholar
|
|
9
|
Garriga J, Bhattacharya S, Calbó J,
Marshall RM, Truongcao M, Haines DS and Graña X: CDK9 is
constitutively expressed throughout the cell cycle, and its
steady-state expression is independent of SKP2. Mol Cell Biol.
23:5165–5173. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu DS and Cortez D: A role for CDK9-cyclin
K in maintaining genome integrity. Cell Cycle. 10:28–32. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Michels AA, Fraldi A, Li Q, Adamson TE,
Bonnet F, Nguyen VT, Sedore SC, Price JP, Price DH, Lania L, et al:
Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb
(CDK9/cyclin T) inhibitor. EMBO J. 23:2608–2619. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Egloff S and Murphy S: Cracking the RNA
polymerase II CTD code. Trends Genet. 24:280–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng J, Marshall NF and Price DH:
Identification of a cyclin subunit required for the function of
Drosophila P-TEFb. J Biol Chem. 273:13855–13860. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou M, Halanski MA, Radonovich MF,
Kashanchi F, Peng J, Price DH and Brady JN: Tat modifies the
activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II
carboxyl-terminal domain during human immunodeficiency virus type 1
transcription. Mol Cell Biol. 20:5077–5086. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pirngruber J, Shchebet A, Schreiber L,
Shema E, Minsky N, Chapman RD, Eick D, Aylon Y, Oren M and Johnsen
SA: CDK9 directs H2B monoubiquitination and controls
replication-dependent histone mRNA 3′-end processing. EMBO Rep.
10:894–900. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Romano G and Giordano A: Role of the
cyclin-dependent kinase 9-related pathway in mammalian gene
expression and human diseases. Cell Cycle. 7:3664–3668. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo
Y, Shyr Y and Cortez D: Cyclin-dependent kinase 9-cyclin K
functions in the replication stress response. EMBO Rep. 11:876–882.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu H and Herrmann CH: Differential
localization and expression of the Cdk9 42k and 55k isoforms. J
Cell Physiol. 203:251–260. 2005. View Article : Google Scholar
|
|
19
|
Siemeister G, Luecking U, Wagner C, Detjen
K, Mc Coy C and Bosslet K: Molecular and pharmacodynamic
characteristics of the novel multi-target tumor growth inhibitor ZK
304709. Biomed Pharmacother. 60:269–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Storch K, Eke I, Borgmann K, Krause M,
Richter C, Becker K, Schröck E and Cordes N: Three-dimensional cell
growth confers radioresistance by chromatin density modification.
Cancer Res. 70:3925–3934. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mazzeo E, Hehlgans S, Valentini V, Baumann
M and Cordes N: The impact of cell-cell contact, E-cadherin and EGF
receptor on the cellular radiosensitivity of A431 cancer cells.
Radiat Res. 178:224–233. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cordes N, Frick S, Brunner TB, Pilarsky C,
Grützmann R, Sipos B, Klöppel G, McKenna WG and Bernhard EJ: Human
pancreatic tumor cells are sensitized to ionizing radiation by
knockdown of caveolin-1. Oncogene. 26:6851–6862. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eke I, Sandfort V, Storch K, Baumann M,
Röper B and Cordes N: Pharmacological inhibition of EGFR tyrosine
kinase affects ILK-mediated cellular radiosensitization in vitro.
Int J Radiat Biol. 83:793–802. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai D, Latham VM Jr, Zhang X and Shapiro
GI: Combined depletion of cell cycle and transcriptional
cyclin-dependent kinase activities induces apoptosis in cancer
cells. Cancer Res. 66:9270–9280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gojo I, Zhang B and Fenton RG: The
cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in
multiple myeloma cells through transcriptional repression and
down-regulation of Mcl-1. Clin Cancer Res. 8:3527–3538.
2002.PubMed/NCBI
|
|
26
|
Ramanathan Y, Rajpara SM, Reza SM, Lees E,
Shuman S, Mathews MB and Pe'ery T: Three RNA polymerase II
carboxyl-terminal domain kinases display distinct substrate
preferences. J Biol Chem. 276:10913–10920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sinclair WK and Morton RA: X-ray
sensitivity during the cell generation cycle of cultured Chinese
hamster cells. Radiat Res. 29:450–474. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simone C, Bagella L, Bellan C and Giordano
A: Physical interaction between pRb and cdk9/cyclinT2 complex.
Oncogene. 21:4158–4165. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lundberg AS and Weinberg RA: Functional
inactivation of the retinoblastoma protein requires sequential
modification by at least two distinct cyclin-cdk complexes. Mol
Cell Biol. 18:753–761. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bowe DB, Kenney NJ, Adereth Y and
Maroulakou IG: Suppression of Neu-induced mammary tumor growth in
cyclin D1 deficient mice is compensated for by cyclin E. Oncogene.
21:291–298. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bartkowiak B, Liu P, Phatnani HP, Fuda NJ,
Cooper JJ, Price DH, Adelman K, Lis JT and Greenleaf AL: CDK12 is a
transcription elongation-associated CTD kinase, the metazoan
ortholog of yeast Ctk1. Genes Dev. 24:2303–2316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blazek D, Kohoutek J, Bartholomeeusen K,
Johansen E, Hulinkova P, Luo Z, Cimermancic P, Ule J and Peterlin
BM: The Cyclin K/Cdk12 complex maintains genomic stability via
regulation of expression of DNA damage response genes. Genes Dev.
25:2158–2172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scholz A, Wagner K, Welzel M, Remlinger F,
Wiedenmann B, Siemeister G, Rosewicz S and Detjen KM: The oral
multitarget tumour growth inhibitor, ZK 304709, inhibits growth of
pancreatic neuroendocrine tumours in an orthotopic mouse model.
Gut. 58:261–270. 2009. View Article : Google Scholar
|
